BA
VKTX icon

Bridgewater Associates’s Viking Therapeutics VKTX Stock Holding History

Bridgewater Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
87,859
+16,630
+23% +$537K 0.01% 561
2026
Q1 		$2.32M Sell
71,229
-32,430
-31% -$1.04M 0.01% 623
2025
Q4 		$3.65M Sell
103,659
-19,832
-16% -$703K 0.01% 618
2025
Q3 		$3.25M Buy
+123,491
New +$3.68M 0.01% 594

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bridgewater Associates's VKTX Position: Q2 2026 in Review

Bridgewater Associates increased its Viking Therapeutics (VKTX) stake by 23% in Q2 2026, buying an estimated $537K and bringing the position to 87,859 shares worth $3.43M. The position accounts for 0.01% of the portfolio, ranked #561.

Bridgewater Associates first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.65M in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bridgewater Associates held 87,859 shares of Viking Therapeutics worth $3.43M as of Q2 2026.
  • Bridgewater Associates bought 16,630 Viking Therapeutics shares in Q2 2026, an estimated $537K.
  • Viking Therapeutics made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #561 holding.
  • Bridgewater Associates first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bridgewater Associates's Viking Therapeutics position peaked at $3.65M in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.